| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.jubl.com | |
| Financial Indicators | ||
|---|---|---|
| Market Cap | 10,942.61 Cr. | |
| Earnings per share (EPS) | 57.03 | Trailing Twelve Months Ending 2021-06 |
| Price-Earning Ratio (PE) | 12.05 | Trailing Twelve Months Ending 2021-06 |
| Industry PE | 35.15 | Trailing Twelve Months Ending 2021-06 |
| Book Value / Share | 308.38 | Trailing Twelve Months Ending 2021-06 |
| Price to Book Value | 2.23 | Calculated using Price: 687.00 |
| Dividend Yield | 0.73 | Period Ending 2020-03 |
| No. of Shares Subscribed | 15.93 Cr. | 159,281,139 Shares |
| FaceValue | 1 | |
| Company Profile | ||
|
Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited. The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US. The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology. Business area of the company Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals. Business segments
Awards 2012
2013
2014
2015
2016
2017
|
||
Company Profile
Jubilant Life Sciences (formerly Jubilant Organosys) was incorporated in the year 1978. It’s a public limited company domiciled in India and incorporated under the provisions of Companies Act, 1956. Its shares are listed on BSE Limited and National Stock Exchange of India Limited.
The Pharmaceuticals segment, through its wholly-owned subsidiary Jubilant Pharma Limited, is engaged in manufacturing and supply of APIs, solid dosage formulations, radiopharmaceuticals, allergy therapy products and contract manufacturing of sterile injectables and non-sterile products through six USFDA approved manufacturing facilities in the US, Canada and India and a network of various radiopharmacies in the US.
The Life Science Ingredients segment is engaged in specialty intermediates, nutritional products and life science chemicals through five manufacturing facilities in India. The drug discovery solutions business is served by Jubilant Biosys and the India branded pharmaceuticals business is an Indian venture with a range of pharmaceutical offerings for the domestic market, focusing primarily on products to treat medical conditions in the field of cardiology and diabetology.
Business area of the company
Jubilant Life Sciences is an integrated global pharmaceutical and life sciences company engaged in pharmaceuticals, life science ingredients, drug discovery solutions and India branded pharmaceuticals.
Business segments
Awards
2012
2013
2014
2015
2016
2017
| 1 Day |
|
+0.15% |
| 1 Week |
|
-1.55% |
| 1 Month |
|
-6.24% |
| 3 Month |
|
-14.02% |
| 6 Month |
|
-22.61% |
| 1 Year |
|
-11.97% |
| 2 Year |
|
+54.41% |
| 5 Year |
|
+104.71% |
| 9 years | 2012-03 | 2013-03 | 2014-03 | 2015-03 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | |
| Return on Equity (%) | 2.06 | 7.98 | 5.39 | -1.58 | 14.27 | 17.95 | 16.87 | 12.97 | 17.25 | |
| Return on Capital Employed (%) | 5.79 | 10.19 | 7.92 | 5.72 | 12.42 | 14.44 | 15.21 | 13.06 | 15.07 | |
| Return on Assets (%) | 0.60 | 2.34 | 1.60 | -0.46 | 4.46 | 6.52 | 6.91 | 5.55 | 7.60 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Shh. Funds | 2,257 | 2,476 | 2,627 | 2,454 | 2,966 | 3,436 | 4,087 | 4,809 | 5,604 | |
| Non Curr. Liab. | 3,224 | 3,005 | 2,185 | 4,036 | 3,347 | 3,826 | 3,417 | 4,420 | 4,088 | |
| Curr. Liab. | 2,213 | 2,778 | 3,894 | 2,129 | 2,464 | 1,684 | 2,005 | 2,090 | 2,619 | |
| Minority Int. | 69 | 112 | 158 | -38 | -47 | -52 | 0 | |||
| Equity & Liab. | 7,763 | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 | |
| Non Curr. Assets | 5,466 | 5,810 | 5,936 | 5,904 | 5,864 | 5,951 | 6,267 | 6,734 | 7,272 | |
| Curr. Assets | 2,297 | 2,561 | 2,928 | 2,715 | 2,875 | 2,948 | 3,190 | 4,585 | 5,038 | |
| Misc. Exp. not W/O | ||||||||||
| Total Assets | 7,763 | 8,371 | 8,864 | 8,619 | 8,740 | 8,899 | 9,457 | 11,319 | 12,310 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Net Sales | 4,303 | 5,166 | 5,803 | 5,826 | 5,749 | 5,861 | 7,518 | 9,111 | 9,154 | |
| Other Income | 31 | 30 | 19 | 42 | 13 | 25 | 40 | 36 | 47 | |
| Total Income | 4,335 | 5,196 | 5,822 | 5,869 | 5,763 | 5,886 | 7,558 | 9,147 | 9,202 | |
| Total Expenditure | -3,413 | -4,098 | -4,782 | -5,125 | -4,502 | -4,516 | -5,999 | -7,372 | -7,207 | |
| PBIDT | 922 | 1,098 | 1,040 | 744 | 1,260 | 1,370 | 1,558 | 1,775 | 1,995 | |
| Interest | -238 | -311 | -337 | -368 | -371 | -341 | -284 | -220 | -287 | |
| Depreciation | -221 | -254 | -281 | -288 | -347 | -291 | -415 | -371 | -462 | |
| Taxation | -68 | -152 | -70 | -80 | -155 | -163 | -225 | -327 | -312 | |
| Exceptional Items | -349 | -192 | -214 | -48 | -280 | -35 | ||||
| PAT | 46 | 189 | 138 | -40 | 387 | 575 | 634 | 577 | 898 |
| Particulars | 9 years | 2012-03 Rs. Cr. | 2013-03 Rs. Cr. | 2014-03 Rs. Cr. | 2015-03 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. |
| Cash Fr. Operatn. | 707 | 970 | 772 | 783 | 1,099 | 1,268 | 1,303 | 1,122 | 1,543 | |
| Cash Fr. Inv. | -594 | -500 | -174 | -343 | -313 | -450 | -618 | -1,012 | -327 | |
| Cash Fr. Finan. | -889 | -450 | -414 | -503 | -843 | -686 | -901 | 657 | -1,050 | |
| Net Change | -776 | 20 | 183 | -63 | -56 | 132 | -216 | 767 | 166 | |
| Cash & Cash Eqvt | 263 | 280 | 473 | 392 | 339 | 456 | 244 | 1,005 | 1,231 |
|
Tue, 27 Jul 2021
Intimation Of Record Date For The Purpose Of Declaration Of Dividend For The Financial Year 2020-21 We refer to our letter dated June 4 2021 intimating recommendation by the Board of Directors for a dividend of Rs. 5 (Rupees Five only) per equity share of Re. 1 each for the year ended March 31 2021. The dividend is subject to approval of the shareholders at the ensuing Annual General Meeting (AGM). Pursuant to Regulation 42 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 the Company has fixed Friday August 6 2021 as the Record Date for the purpose of determining names of the Members eligible for the dividend. The dividend if approved by the shareholders at the ensuing AGM will be paid/ dispatched on or before October 20 2021. |
|
Fri, 23 Jul 2021
Announcement under Regulation 30 (LODR)-Scheme of Arrangement In terms of Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 we wish to inform you that the Board of Directors of Jubilant Pharmova Limited (JPM) at its meeting held on July 23 2021 has approved the demerger of the Active Pharmaceutical Ingredients (API) undertaking of Jubilant Generics Limited (JGL - a wholly owned subsidiary of the Company) and vesting of the same with JPM on a going concern basis (Proposed Demerger) to be implemented through a scheme of arrangement between JGL and JPM and their respective shareholders and creditors under Sections 230 to 232 and other applicable provisions of the Companies Act 2013 (Proposed Scheme). The details as required to be disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 read with SEBI Circular dated September 9 2015 are enclosed at Annexure A. Kindly take the above information on record. |
|
Fri, 23 Jul 2021
Results For Quarter Ended June 30 2021 In terms of Regulation 33 read with Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations 2015 (the Listing Regulations) we wish to inform you that the Unaudited Financial Results (Standalone and Consolidated) of the Company for the quarter ended June 30 2021 were approved by the Board of Directors of the Company at its meeting held today at 1:30 p.m. and concluded at 4.00 p.m. Pursuant to the applicable provisions of the Listing Regulations we enclose the following: 1. The Unaudited Financial Results (Standalone and Consolidated) for the quarter ended June 30 2021; 2. Limited Review Reports on the Unaudited Financial Results (Standalone and Consolidated) for the said quarter; and 3. Copies of the Press Release and Presentation. We request you to take the same on records. |
| Fri, 30 Jul 2021 |
Stock Underperforming Benchmark Index in both 1 Week and 3 Month
|
Stock Underperforming Sectoral Index in both 1 Week and 3 Month
|
Strongly Underperforming Benchmark index
|
Strongly Underperforming Sectoral index
|
Both SRS And ARS Below Zero
|
Equities
M.F.
Sectors